These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
118 related items for PubMed ID: 6688844
1. Long-term myocardial preservation: thromboxane production and coronary resistance. van Rijk GL, Foegh M, Ramwell PW, Goldman M, Lower RR. J Surg Res; 1983 Nov; 35(5):417-20. PubMed ID: 6688844 [Abstract] [Full Text] [Related]
2. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart. Sakai K, Ito K, Ogawa K. J Cardiovasc Pharmacol; 1982 Nov; 4(1):129-35. PubMed ID: 6176788 [Abstract] [Full Text] [Related]
3. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. Uyama O, Nagatsuka K, Nakabayashi S, Isaka Y, Yoneda S, Kimura K, Abe H. Stroke; 1985 Nov; 16(2):241-4. PubMed ID: 3883580 [Abstract] [Full Text] [Related]
4. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581. Mehta J, Mehta P, Ostrowski N. Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153 [Abstract] [Full Text] [Related]
5. Reduction of prostacyclin synthesis as a possible cause of transient flow reduction in a partially constricted canine coronary artery. Tada M, Esumi K, Yamagishi M, Kuzuya T, Matsuda H, Abe H, Uchida Y, Murao S. J Mol Cell Cardiol; 1984 Dec; 16(12):1137-49. PubMed ID: 6398370 [Abstract] [Full Text] [Related]
6. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord]. Morimoto K, Ikata T, Tounai T. Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197 [Abstract] [Full Text] [Related]
7. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y, Hattori R, Takatsu Y, Nakajima H, Wakabayashi A, Kawai C, Kayama N, Hiraku S, Inagawa T, Tsubojima M. Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [Abstract] [Full Text] [Related]
12. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. Shikano M, Ito T, Ogawa K, Satake T. Jpn Heart J; 1987 Sep 24; 28(5):663-74. PubMed ID: 3323562 [Abstract] [Full Text] [Related]
13. The protective effect of thromboxane A2 synthetase inhibitor against ischemic liver injury. Isozaki H, Okajima K, Hara H, Kobayashi M. Surg Today; 1994 Sep 24; 24(5):435-40. PubMed ID: 8054815 [Abstract] [Full Text] [Related]
15. Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Ritter JM. Br J Pharmacol; 1984 Oct 24; 83(2):409-18. PubMed ID: 6386089 [Abstract] [Full Text] [Related]
16. Beneficial effect of thromboxane A2 synthetase inhibitor (OKY-046) on 24-hr simple hypothermic preservation of the canine pancreas graft. Nagami H, Tamura K, Kin S, Teramoto M, Ishida T. Int Surg; 1995 Oct 24; 80(3):274-7. PubMed ID: 8775620 [Abstract] [Full Text] [Related]